相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pathophysiology of diabetes mellitus and its complications: Metabolic events and control
Franklyn O. Ohiagu et al.
BIOMEDICAL RESEARCH AND THERAPY (2021)
Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis
Manal S. Fawzy et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2020)
Fucoidan Ameliorates Oxidative Stress, Inflammation, DNA Damage, and Hepatorenal Injuries in Diabetic Rats Intoxicated with Aflatoxin B1
Mohammed S. Aleissa et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
Protective effects of Artemisia judaica extract compared to metformin against hepatorenal injury in high-fat diet/streptozotocine-induced diabetic rats
Gadah Albasher et al.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (2020)
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
FRONTIERS IN ENDOCRINOLOGY (2019)
Type 1 Diabetes-related Autoantibodies in Different Forms of Diabetes
Elin Pettersen Sorgjerd
CURRENT DIABETES REVIEWS (2019)
Red onion scales ameliorated streptozotocin-induced diabetes and diabetic nephropathy in Wistar rats in relation to their metabolite fingerprint
Tarek Kamal Abouzed et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Rebirth of the Incretin Concept: Its conception and early development
Vincent Marks
PEPTIDES (2018)
Adipose-derived stem cells: Effectiveness and advances in delivery in diabetic wound healing
Mohamed Gadelkarim et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity
Mostafa Wanees Ahmed El Husseny et al.
JOURNAL OF DIABETES RESEARCH (2017)
Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system
Robert S. Zimmerman et al.
DIABETES OBESITY & METABOLISM (2017)
Spirulina platensis prevents hyperglycemia in rats by modulating gluconeogenesis and apoptosis via modification of oxidative stress and MAPK-pathways
Kadry M. Sadek et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis
Bruno Geloneze et al.
DRUGS (2017)
Incretins, Pregnancy, and Gestational Diabetes
Dragana Nikolic et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2016)
Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality
Masashi Shimoda et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
Xiao-Wu Chen et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2015)
Teneligliptin: expectations for its pleiotropic action
Ryuichi Morishita et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Incretin and Glucagon Levels in Adult Offspring Exposed to Maternal Diabetes in Pregnancy
Louise Kelstrup et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Incretin Effect After Oral Amino Acid Ingestion in Humans
Ola Lindgren et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation
Ruijun Han et al.
SCIENTIFIC REPORTS (2015)
Mathematical Modeling of Interacting Glucose-Sensing Mechanisms and Electrical Activity Underlying Glucagon-Like Peptide 1 Secretion
Michela Riz et al.
PLOS COMPUTATIONAL BIOLOGY (2015)
Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
Elizabeth S. Ommen et al.
DIABETES THERAPY (2015)
Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
Elizabeth S. Ommen et al.
DIABETES THERAPY (2015)
Incretin physiology and pathophysiology from an Asian perspective
Young Min Cho
JOURNAL OF DIABETES INVESTIGATION (2015)
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill et al.
ENDOCRINE REVIEWS (2014)
Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells
Diana Roehrborn et al.
FEBS LETTERS (2014)
Biochemical efficacy of vitamin D in ameliorating endocrine and metabolic disorders in diabetic rats
Kadry M. Sadek et al.
PHARMACEUTICAL BIOLOGY (2014)
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
Na-Hyung Kim et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Daniel Lorber
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2014)
Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes
Stuart A. Ross
AMERICAN JOURNAL OF MEDICINE (2013)
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Jixin Zhong et al.
ATHEROSCLEROSIS (2013)
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Mika Nabeno et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Adipose Dipeptidyl Peptidase-4 and Obesity Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro
Henrike Sell et al.
DIABETES CARE (2013)
Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
Nasib Ervinna et al.
ENDOCRINOLOGY (2013)
Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: Mechanisms of Diabetes Remission and Role of Gut Hormones
M. Nannipieri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
Shinji Furuta et al.
XENOBIOTICA (2013)
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
Sheldon Russell
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2013)
Sitagliptin Exerts an Antinflammatory Action
Antoine Makdissi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
Michael A. Nauck
AMERICAN JOURNAL OF MEDICINE (2011)
Glucagon-like peptide 1 and the brain: Central actions-central sources?
Stefan Trapp et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2011)
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Daniela Lamers et al.
DIABETES (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
Mark Kirby et al.
CLINICAL SCIENCE (2010)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
Molecular Mechanism of Insulin Resistance in Obesity and Type 2 Diabetes
Kangduk Choi et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2010)
Improvement in Glucose Metabolism After Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy A Prospective Randomized Trial
Ralph Peterli et al.
ANNALS OF SURGERY (2009)
On the origin of serum CD26 and its altered concentration in cancer patients
Oscar J. Cordero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Unraveling the Science of Incretin Biology
Michael A. Nauck
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2009)
The incretin system and its role in type 2 diabetes mellitus
Jens Juul Holst et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Incretin and islet hormonal responses to fat and protein ingestion in healthy men
Richard D. Carr et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
β-Cell Failure in Type 2 Diabetes Mellitus
Cristina Lencioni et al.
CURRENT DIABETES REPORTS (2008)
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
J. -F. Gautier et al.
DIABETES & METABOLISM (2008)
Fibroblast activation protein and chronic liver disease
Xin Maggie Wang et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation
William J. Metzler et al.
PROTEIN SCIENCE (2008)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress
Bernardo Yusta et al.
CELL METABOLISM (2006)
Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors
Kenton L. Longenecker et al.
BIOCHEMISTRY (2006)
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
Tingcun Zhao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Rigidity and flexibility of dipeptidyl peptidase IV: Crystal structures of and docking experiments with DPIV
M Engel et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis
Denise M. T. Yu et al.
FEBS JOURNAL (2006)
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line
XM Wang et al.
HEPATOLOGY (2005)
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
MA Nauck et al.
REGULATORY PEPTIDES (2005)
Glucagon-like peptide 1(GLP-1) in biology and pathology
JJ Meier et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
A Hirasawa et al.
NATURE MEDICINE (2005)
Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation
K Aertgeerts et al.
PROTEIN SCIENCE (2004)
Review of the performance of methods to identify diabetes cases among vital statistics, administrative, and survey data
SH Saydah et al.
ANNALS OF EPIDEMIOLOGY (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nyström et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function
K Kristiansen
PHARMACOLOGY & THERAPEUTICS (2004)
Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface
WA Weihofen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance
E Rask et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
L Farilla et al.
ENDOCRINOLOGY (2003)
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
M Yu et al.
JOURNAL OF HYPERTENSION (2003)
The G-protein-coupled receptors in the human genome form five main families.: Phylogenetic analysis, paralogon groups, and fingerprints
R Fredriksson et al.
MOLECULAR PHARMACOLOGY (2003)
A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line
FM Gribble et al.
DIABETES (2003)
The crystal structure of dipeptidyl peptidase IV(CD26) reveals its functional regulation and enzymatic mechanism
M Engel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog
HB Rasmussen et al.
NATURE STRUCTURAL BIOLOGY (2003)
Regulation of pancreatic β-cell glucokinase -: From basics to therapeutics
FM Matschinsky
DIABETES (2002)
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Q Wang et al.
DIABETOLOGIA (2002)
Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family
AM Lambeir et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo
Q Xiao et al.
BIOCHEMISTRY (2001)
Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients
T Vilsboll et al.
DIABETES (2001)
New perspectives into the molecular pathogenesis and treatment of Type 2 diabetes
AR Saltiel
CELL (2001)
Effect of GLP-1 on lipid metabolism in human adipocytes
ML Villanueva-Peñacarrillo et al.
HORMONE AND METABOLIC RESEARCH (2001)
Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes
FJ Salgado et al.
CYTOKINE (2000)
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
DA Stoffers et al.
DIABETES (2000)
Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells
B Bauvois et al.
ONCOGENE (2000)
分享论文
